Elion Therapeutics is dedicated to developing innovative therapies for invasive fungal infections, focusing on addressing significant unmet needs in antifungal efficacy and safety. The company is advancing its pipeline with SF001, a next-generation polyene therapy designed for intravenous infusion. This investigational drug, which is a micellar solution of Sfu-AM2-19A, has shown promising results in nonclinical studies, demonstrating potent fungicidal activity both in vitro and in vivo. In recognition of its potential, SF001 has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA, facilitating its development for serious infections such as invasive aspergillosis.

The scientific foundation of Elion Therapeutics' approach lies in the discovery of how amphotericin B interacts with sterols, which are crucial for cell membrane integrity in both fungal and human cells. This understanding has led to the rational design of SF001, aimed at enhancing specificity for fungal cells while minimizing systemic toxicities associated with traditional polyene therapies. By leveraging insights from academic research and applying rational drug design principles, Elion Therapeutics is positioned to create more effective and safer antifungal treatments, ultimately transforming the landscape of care for patients suffering from invasive fungal infections.

United States

Elion Therapeutics is a cutting-edge biotechnology company dedicated to transforming the treatment of life-threatening fungal infections using a novel approach that’s rooted in structural chemistry. Elion was founded with the belief that mechanistic insights enable targeted optimizations of natural products. Today, Elion is advancing the first polyene antifungal rationally designed to mitigate toxicities and increase safety.

Elion Therapeutics

Company Details